James M. O’Brien joined Cognition Therapeutics as chief financial officer in November 2019. Mr. O’Brien has a track record of performance in capital raising and business development, strategic planning, acquisitions and operations at public as well as entrepreneurial private companies in the life sciences. Prior to joining Cognition, he served as the executive vice president of finance at Enzo Biochem, Inc., a public company with revenues of over $100 million. Before Enzo, Mr. O’Brien was vice president and corporate controller at Allergan, Inc., where he integrated several international business acquisitions and managed collaboration activities valued at nearly $10 billion. Earlier in his career, he held positions at life sciences companies including Nycomed and Bristol-Myers Squibb, and spent close to a decade at PricewaterhouseCoopers. Mr. O’Brien is a certified public accountant with a Bachelor of Accountancy from George Washington University and a Master of Business Administration from Fordham University.